Free Trial
NASDAQ:PRTA

Prothena Q1 2024 Earnings Report

Prothena logo
$4.61 +0.02 (+0.44%)
As of 10:50 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Prothena EPS Results

Actual EPS
-$1.34
Consensus EPS
-$1.21
Beat/Miss
Missed by -$0.13
One Year Ago EPS
-$0.89

Prothena Revenue Results

Actual Revenue
$0.05 million
Expected Revenue
$3.75 million
Beat/Miss
Missed by -$3.70 million
YoY Revenue Growth
N/A

Prothena Announcement Details

Quarter
Q1 2024
Time
After Market Closes
Conference Call Date
Wednesday, May 8, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Prothena's Q2 2025 earnings is scheduled for Thursday, August 7, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Prothena Earnings Headlines

HC Wainwright Has Weak Outlook for Prothena FY2027 Earnings
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Revolution we predicted has arrived." In fact, I believe these robots could impact 65 million Americans lives — by August of this year.
Prothena (NASDAQ:PRTA) Given Underperform Rating at Bank of America
See More Prothena Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prothena? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prothena and other key companies, straight to your email.

About Prothena

Prothena (NASDAQ:PRTA), a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

View Prothena Profile

More Earnings Resources from MarketBeat